[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:cd79b-gene":3},{"name":4,"total":5,"recruiting":5,"trials":6},"CD79B Gene",2,[7,15],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT06846463","Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+",[11],"Phase 2","RECRUITING","2026-08-26T02:19:13.549512Z","2026-05-05T02:43:28.810232Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT05773040","A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas",[19],"Phase 1","2026-08-26T02:19:30.857183Z","2026-05-05T02:35:31.752653Z"]